Inflexion returns 2.8x on sale of Phlexglobal
Inflexion Private Equity is pleased to announce the sale of Phlexglobal. Phlexglobal is the leading provider of technology-enabled document management solutions to the global clinical research market. Inflexion has realised a return of 2.8x on its original investment from a secondary buyout to Bridgepoint Development Capital.
Inflexion’s original investment facilitated the founder transitioning out of the business and provided an opportunity to strengthen the leadership team with the appointment of a CEO and CTO. Working closely with Inflexion, the management team has rapidly expanded its international operations, opening a new office in the US to target major North American pharma clients. Phlexglobal was also able to accelerate investment in its core technology platform and its service provision establishing it as the clear market leader.
Simon Turner, Managing Partner at Inflexion said “We are proud that under our ownership Phlexglobal has doubled profits, expanded its international footprint and strengthened its service capability. We backed an experienced management team led by Stella Donoghue and we were able to recruit a highly regarded, tenacious, Chairman, Steven Kent. We have enjoyed a great working relationship with Steven and the whole team. The company is now well positioned to capitalise on its next stage of growth with Bridgepoint Development Capital and we wish the team every success in the future.”
Stella Donoghue, CEO at Phlexglobal said “Inflexion has been a highly supportive investor. The management team have been able to make the investments in our people and technology to grow our business. We have enjoyed working with Inflexion in the UK and utilising their wider team to assess the international opportunities in India and Asia Pacific. Together we have built a business that we are very proud of.”
The sale process was led by Richard Swann and Edward Fraser. Inflexion was advised by BDO.